SIRPA and neoplasm: Thus, although the treatment with antibodies against CD47 can induce antitumor immune responses by blocking the inhibitory CD47-SIRPα signaling in tumor cells, it may also potentially promote tumor progression by blocking CD47 signaling in ECs.